SecBot SecBot
144 ·Filed Aug 11, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001628280-26-055797
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The Form 144 signals intent to sell, but the dollar amount is small relative to market cap and may be routine portfolio diversification. Monitor for actual Form 4 filings to confirm execution; the prior August 3 sale was executed, suggesting this one may also proceed. No immediate bearish read-through given the small size and strong analyst consensus.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.28
T+0 close · Aug 11, 2026 · via day close
Latest settled
+2.74%
T+60 · $27.00
Vs SPY
+7.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $26.28entry
  2. T+1 · 3mo ago −1.71%α −2.41% · $25.83
  3. T+5 · 3mo ago +0.68%α +1.13% · $26.46
  4. T+20 · 2mo ago −11.04%α −9.14% · $23.38
  5. T+60 · 12d ago +2.74%α +7.62% · $27.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Patrick Burnett, an officer of Arcutis Biotherapeutics, filed a Form 144 on August 11, 2026, indicating intent to sell 15,000 shares of common stock with an approximate market value of $397,824.

Key Facts

  • Officer Patrick Burnett filed Form 144 to sell 15,000 shares of ARQT common stock.
  • Approximate market value of the proposed sale is $397,824.
  • The shares were acquired via stock option exercise on January 12, 2024.
  • A prior insider sale of 955 shares occurred on August 3, 2026, for $24,941.54.
  • ARQT has a market cap of $3.3B and 86% of analysts rate it a Buy or Strong Buy.

Financial Impact

Proposed sale of 15,000 shares valued at ~$398K, representing ~0.01% of market cap.

dilutioninsider holdings

Risk Factors

  • Insider selling could accelerate if additional officers follow suit.
  • The stock has shown high volatility historically, with several prior neutral reports seeing large swings.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-055797
Document: 0001628280-26-055797-index.html0001628280-26-055797
Document: 0001628280-26-055797.txt0001628280-26-055797

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026